Biotech

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). As quoted in the press release: NF1 is an incurable genetic condition that affects one in 3,000 …

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, today announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

As quoted in the press release:

NF1 is an incurable genetic condition that affects one in 3,000 newborns worldwide. The severity of signs and symptoms associated with NF1 can be highly variable, are often mild-to-moderate and may include skin, nerve and skeletal manifestations.Plexiform neurofibromas (PNs) are benign tumors on nerve sheaths that develop in 20-50 percent of patients and, as they continue to increase in number and size, cause moderate-to-severe morbidities such as pain, motor dysfunction and disfigurement.

Sean Bohen, executive vice president, global medicines development and chief medical officer, at AstraZeneca, said, “There is no cure for NF1, a life-long and devastating condition, and current treatment choices for these patients are very limited. The granting of an orphan designation is a positive step forward for children with NF1 and their families.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20083.22-538.17
TSXV811.00-45.62
DOW33545.73-719.64
S&P 5004281.52-116.42
NASD13343.68-425.24
ASX7175.80-166.60

COMMODITIES

Commodities
Gold1833.74-0.45
Silver23.65-0.62
Copper4.41-0.11
Palladium2148.00+51.00
Platinum1018.00-12.00
Oil82.57-2.57
Heating Oil2.58-0.06
Natural Gas4.01+0.01

DOWNLOAD FREE REPORTS

×